Critical Contrast: Petros Pharmaceuticals (NASDAQ:PTPI) and Eagle Pharmaceuticals (NASDAQ:EGRX)

Earnings & Valuation

This table compares Petros Pharmaceuticals and Eagle Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11 million	0.08	-$8.16 million	($39.69)	0.00
Eagle Pharmaceuticals	$257.55 million	0.03	$35.64 million	$1.18	0.47

Eagle Pharmaceuticals has higher revenue and earnings than Petros Pharmaceuticals. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 12.3% of Petros Pharmaceuticals shares are owned by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Petros Pharmaceuticals has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Profitability

This table compares Petros Pharmaceuticals and Eagle Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Eagle Pharmaceuticals	N/A	N/A	N/A

Summary

Eagle Pharmaceuticals beats Petros Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.